HomeLBank Stocks
Aldeyra The
Aldeyra The

Aldeyra The (ALDX)

24HHigh$0.8824HLow$0.66
$0.84
+0.22%

Last updated: 2026-11-21 11:10:25

K-Line Chart, actual market data is subject to the trading page.

Key Data

Prev. Open
$0.69
Prev. Close
$0.84
Prev. Day's Range
$0.66 - $0.88
52W Range
$0.53 - $5.93
Trading Volume
2.382M
MC
$43.559M
P/E Ratio
--
EPS
$-0.31

Company Overview

NASDAQ

Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters131 HARTWELL AVENUE, LEXINGTON, MA, UNITED STATES, 02421
CountryUSA
Listing Date2014-05-02
Fiscal Year Ended2026-09-30
Shares Outstanding60.357M
CIK Code1341235

Financial Metrics

Indicator2026-06-302026-03-312025-12-312025-09-30
Income$0$0$0$0
Operating Expenses--$66.599K$65.115K$63.683K
Net Income-$5.45M-$3.453M-$6.462M-$7.688M
Net Profit Margin--------
Earnings Per Share--$-0.06$-0.11$-0.13
EBITDA-$5.38M-$2.917M-$5.921M-$7.149M
Effective Tax Rate--------

FAQ

Aldeyra Therapeutics specializes in biotechnology and pharmaceutical development. It focuses on pioneering therapies for immune-mediated diseases and retinal ailments. The company leverages its expertise in aldehyde reduction technology to target oxidative stress-related disorders, offering novel therapeutic solutions in areas of unmet medical need.
Aldeyra Therapeutics operates in the healthcare sector, specifically within the biotechnology and pharmaceutical industry. Companies in this space are often focused on research, drug development, and clinical trials for breakthrough therapies to address complex health conditions.
Key opportunities include Aldeyra’s focus on high-potential markets and therapies addressing unmet clinical needs. The company's pipeline of drugs, if successfully approved, could establish its presence in lucrative niches. Risks involve dependency on regulatory approvals, potential delays in clinical trials, and the competitive biotech landscape, which may impact market share and commercialization efforts.
Aldeyra Therapeutics does not currently pay dividends. As a biotechnology company focused on drug development, it typically reinvests profits into research and development. Dividend payments are less common in this industry because of long product development cycles and high upfront costs.
Aldeyra Therapeutics' revenue growth is primarily driven by its ability to advance drug candidates through clinical trials, obtain regulatory approvals, and successfully commercialize its therapies. Collaborations, licensing agreements, and funding for research also contribute significantly to its financial profile.
Aldeyra Therapeutics competes with other biotechnology companies specializing in immune-mediated diseases and ophthalmology, such as Regeneron Pharmaceuticals and Allergan. Competition largely revolves around innovation, obtaining market approvals, and bringing treatments to patients ahead of rivals.
Clinical trials are crucial to Aldeyra Therapeutics' growth as they determine the safety and efficacy of its drug candidates. Successful trials pave the way for regulatory approval, commercialization, and potential revenue generation, which are key to scaling operations in the competitive biotech industry.
Valuation for Aldeyra Therapeutics often depends on the progress of clinical trials, market potential for its drug pipeline, and investor expectations for future growth. Challenges such as regulatory hurdles and competition may impact valuation, while successful innovation and approvals can enhance it.
Risk Warning
  1. 1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
  2. 2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
  3. 3.The information contained on this page is for reference only and does not constitute any investment advice.